was conducted to compare gender-based post diagnosis survival and disease progression. Statistical significance was 95% confidence level (p < 0.05). Result: Among 7738 lung cancer patients, 95.6% (3743/ 7738) were NSCLC: 52% male and 48% female. Significant genderbased differences were observed in histology (p¼0.00). SCC and ADC were the most frequent histology in both genders. However, ADC was commoner in women (49% vs 41%), while SCC was commoner in men (27% vs 17%). Relative changes of ADC rate over 15 years have increased significantly among women compared to men (58% vs 32%, P<0.02). The risk of developing NSCLC was greatly elevated with cigarette consumption in both genders; however, ADC in never smokers was higher in women (18%) compared to men (8%). Among ADC, smoking history and gender both showed a significant effect on survival, where mOS for never-smokers females exceeded that of neversmokers males [20 months vs 14 months, 95%CI, P¼0.00]. The same trend was also seen in smokers [13 months vs 7 months, 95%CI, P¼0.021]. In addition, the OS among male ADC cases was significantly lower than women of all tumor stages (P¼0.00), but these disparities were insignificant across genders with SCC (P¼0.46). Conclusion: Similar to what we observed in our systematic review, gender influences the clinical course of NSCLC regardless of smoking history or stage in Southern Alberta. Identifying the cause of the increase in ADC rate over 15 years in women and higher prevalence of NSCLC in never smoking women warrants aggressive research strategies.
P2.01-06 HSP72 Expression Associates with Survival in EGFR Mutated NSCLC I. Amanam, 1 P. Frankel, 2 S. Mach, 2 E. Dickinson, 2 L. Zheng, 1 B. Shen, 2 K. Reckamp 2 1 City of Hope, Duarte, CA/US, 2 City of Hope, Duarte, CA/US Background: Heat shock protein 72 (HSP72) was observed to be important for editing DNA replication errors and repairing base damage. EGFR mediates HSP72 Y41 stability via phosphorylation. EGFR tyrosine kinase inhibitor (EGFR-TKI) therapy inhibited phosphorylation of HSP72 leads to its degradation with suppression of polymerase a (Pola) and a resultant increase in overall mutation rate in EGFR mutant lung cancer cells. Our primary objective was to determine if baseline HSP72 expression is a prognostic biomarker for NSCLC patients with EGFR mutant NSCLC. Method: A retrospective cohort of patients was identified with known EGFR mutation positive NSCLC and available tissue from the City of Hope Comprehensive Cancer Center seen between 2008 and 2016. Immunohistochemical (IHC) analysis was performed to analyze HSP72 levels. A chi-square test for categorical data and multivariate logistic regression analyses was used to study the relation between HSP72 expression and the other clinical and demographic data. Result: 48 patients with EGFR mutated NSCLC and available tissue were identified. The median age was 64 range (39-84) with 50% Asian (n ¼ 24), Caucasian 38% (n ¼ 18), and African American 8% (n ¼ 4) and other 4% (n ¼ 2). Most patients were Stage IV at initial diagnosis (n ¼ 41, 85%), other were Stage IB (n ¼ 2), Stage IIB (n ¼ 1), Stage IIIA (n ¼ 1) and Stage IIIB (n ¼ 3). HSP72 expression was 0 in 16 patients, 1 in 15 patients, 2 in 9 patients and 3 in 8 patients. Median survival of HSP72 0, 1, 2,3 were 28.3, 42.4, 41.2, and 107.7 months respectively (p < 0.02, log-rank test). In univariate Cox regression analysis, HSP72 expression of 3 compared to others correlated with an HR of 0.23 (95% CI 0.07-0.77). When stratifying by stage (Stage IV vs all others), the HR associated with an HSP72 expression of 3 was 0.22 (95% CI 0.05-0.97), and the signal for HSP72 was also significant when stratifying by stage and considering HSP72 score as either a continuous marker or as the four categories (0,1,2,3). There was no relationship noted in the change in HSP72 values as tumors transformed from T790M-to T790M+, and no relationship related to Background: Lattice radiotherapy (LRT) is a novel technique of delivering heterogeneous doses of radiation for the management of voluminous tumors which are not amenable to surgical resection. Built from the conventional 2-dimensional GRID, LRT utilizes the power of new technology in the field of radiation therapy to implement 3dimensional dosimetry plans. LRT allows delivery of higher doses of radiation to small spheres, also called vertices, in the interior of the bulky tumors limiting the exposure of surrounding healthy tissue to unacceptably high doses of radiation. Method: Ten patients with nonsmall cell lung cancer (NSCLC): Nine males and 1 female, with ages from 49 to 87 with a median of 70 who presented with bulky, unresectable primary tumors were treated with LRT during a 7-year period. Follow-up ranged from 4 to 73 months with a median of 10 months. All patients received one initial LRT fraction of 18 Gy in the lattice vertices and 3 Gy in the tumor periphery. All patients continued treatment with conventional radiation given in 25 to 33 daily fractions of 1.8 Gy to 2 Gy each. Image guided radiation therapy IGRT with CBCT and Volumetric Arc Therapy technique were used in all patients. Result: There was no associated morbidity or mortality to the addition of LRT in these patients. There was a significant decrease in tumor volume from the time of planning CT to the last f treatment imaging. Conclusion: In this early experience, LRT appears to be a safe and effective modality of treatment for bulky NSCLC. LRT should be considered for non-surgical patients presenting with voluminous tumors. It is postulated that this technique induces changes in the tumor microenvironment leading to a more effective tumor control. More research is needed to elucidate the mechanisms by which LRT is effective in the reduction of tumor size. Keywords: Voluminous Tumors, Lattice Radiotherapy, GRID Therapy P2.01-08 Conversion Surgery for Locally Advanced Lung Adenocarcinoma Harboring Driver Gene Mutation After TKI Followed by Cytotoxic Agent M. Aoki, T. Umehara, G. Kamimura, T. Tokunaga, T. Nagata, A. Takeda, N. Yokomakura, K. Kariatsumari, M. Yanagi, M. Sato Department of General Thoracic Surgery, Kagoshima University, Kagoshima/JP Background: The optimal treatment of locally advanced non-small cell lung cancer including stage IIIA still remains controversial. For lung adenocarcinoma harboring driver gene mutation, it has been reported that tyrosine kinase inhibitor (TKI) shows great tumor response and downstaging. Moreover, some reports showed its usefulness of salvage surgery after TKI treatment. Method: Between January 2016 and April 2017, we performed surgical resection for five non-small cell lung cancer patients who underwent TKI followed by platinum agent and pemetrexed treatment at Kagoshima University Hospital. All patients were diagnosed as having c-stageIIIA (three patients with c-T2aN2M0 and each one patient with c-T4N1M0 and c-T3N2M0) lung adenocarcinoma harboring driver gene mutation (four patients with EGFR mutation and one patient with EML4-ALK rearrangement) by preoperative examinations (Computed Tomography, 18F-fluorodeoxyglucose Positron Emission Tomography, brain Magnetic Resonance Imaging and bronchoscopic examination). Because these patients initially had locally advanced tumor burden or mediastinal lymph nodes metastasis, onestage radical surgery would not have been feasible. Therefore, these patients received TKI administration for less than six months, followed by two cycles of platinum agent and pemetrexed treatment before the operation. After the operation, three patients received two or four cycles platinum agent and pemetrexed treatment, however, the other two patients did not receive additional treatment. We obtained informed consent from all the patients before the beginning of treatment. Result: In all patients, the effect on tumor response of TKI followed by platinum agent and pemetrexed treatment was shown. In addition, the complete resection was confirmed microscopically. None of these patients experienced disease flare after stopping TKI administration. The exon 20 T790M mutation gene was not found in all resected specimens with EGFR mutation. There were no postoperative major complications and mortality. Brain metastasis appeared in one patient who did not receive postoperative chemotherapy six months after the operation. This patient was managed successfully with gamma knife radiotherapy. All the five patients are now under follow-up treatment with no local recurrence. Conclusion: Conversion Surgery after TKI followed by platinum agent and pemetrexed treatment can become feasible and useful strategy for locally advanced lung adenocarcinoma harboring driver gene mutation. Background: KRAS mutant (m) non-small cell lung cancer (NSCLC) represents 25% of cases. Despite the common mutation, biological and clinical behaviour of this disease is diverse. The aim of our study was to analyze co-occurring genomic alterations in advanced KRASm lung by next-generation sequencing (NGS) and compare them to a KRAS wildtype (WT) population. Method: Advanced lung adenocarcinoma patients treated with a platinum doublet with KRAS mutation by Sanger were submitted to targeted NGS with the Oncomine Solid Tumor kit (DNA) and compared to a KRAS WT population of clinically similar patients. Association with outcome of the genomic alterations was evaluated. Result: 32 KRASm patients and 18 WT patients were analyzed. The most frequent KRAS mutation was p.Gly12Cys (45%), followed by p.Gly12Val (24%). TP53 mutation was observed in 55% of KRASm tumors and 60% of WT cases (Table 1) . Mutations in STK11 were found in 10% of cases in the KRAS mutant cohort while none in the WT. 3 out of the 4 cases of STK11 mutations coexisted with TP53 mutations. FGFR3, SMAD4 and DDR2 mutations were more frequently found in cases with KRAS mutations, although at low frequencies.
Neither KRAS nor TP53 mutations had an impact in OS. We then selected the KRAS mutant cohort and evaluated the impact of co-mutations. TP53 or STK11 did not significantly affect OS of KRAS mutant patients. Conclusion: KRASm lung adenocarcinoma is genomically diverse. NGS provides biologically relevant information and druggable targets in this subset of patients (NSCLC) . We aimed to develop novel biomarkers reflecting longitudinal change of radiomic features in NSCLC and evaluate prognostic power of those. Method: Fifty-three patients with advanced NSCLC included in this retrospective study. Measurable lesions on baseline and follow-up computed tomography (CT) were segmented and 23 radiomic features were extracted. All three variables reflecting patterns of longitudinal change were extracted: the area under the curve (AUC), beta value, and AUC2. We constructed models for predicting survival using multivariate cox regression, and identified the performance of these models. Result: In volume, AUC2 showed an excellent correlation with pattern of longitudinal volume change (r ¼ 0.848, p < 0.000), and showed a significant difference in overall survival time (p ¼ 0.035). In multivariate regression analysis, kurtosis of positive pixel values (p < 0.000), and surface area (p ¼ 0.001) on baseline CT, and AUC2 of density (p < 0.000), skewness of positive pixel values (p ¼ 0.003), and entropy at inner (p ¼ 0.001) were found to be associated with overall survival time, and the area under the receiver operating characteristics curves were 0.922, and 0.771 at 1 year, and 3 years of follow-up. 
